EYPT FY 2023 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+11.1% YoY

Gross Profit

$41M89.9% margin

Operating Income

-$75M-163.1% margin

Net Income

-$71M-153.8% margin

EPS (Diluted)

$-1.82

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$355M

Total Liabilities

$89M

Stockholders' Equity

$266M

Cash & Equivalents

$281M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$41M	+11.1%
Gross Profit	$41M	$33M	+25.1%
Operating Income	-$75M	-$100M	+24.7%
Net Income	-$71M	-$102M	+30.8%